Evidence map›Paper›PMID 41439974›Full record

ArticleCells2025

Does Antenatal Lactoferrin Protect Hippocampal Development in Ovine Fetuses with Growth Restriction?

Dahyun Kang, Ingrid Dudink, Tegan A White, Amy E Sutherland, Tamara Yawno, Yen Pham, Petra S Huppi, Stéphane V Sizonenko, Suzanne L Miller, Beth J Allison

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dahyun KangThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0009-0006-8292-4224
Ingrid DudinkThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.
Tegan A WhiteThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0000-0001-8809-3448
Amy E SutherlandThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0000-0002-4807-2340
Tamara YawnoThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0000-0002-4257-3814
Yen PhamThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.
Petra S HuppiDepartment of Pediatrics, Gynecology and Obstetrics University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0002-7383-6648
Stéphane V SizonenkoDepartment of Pediatrics, Gynecology and Obstetrics University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0003-0093-8747
Suzanne L MillerThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0000-0002-0451-8304
Beth J AllisonThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia.ORCID 0000-0002-1060-513X

Funding

Cerebral Palsy Alliance PRG09231National Health and Medical Research Council of Australia 1175843National Health and Medical Research Council of Australia 2016688
6 · The paper itself

Abstract

Early-onset fetal growth restriction (FGR) is associated with prolonged fetoplacental hypoxia and altered brain development, including deficits in hippocampal structure and function. Neuroprotective actions of lactoferrin have been described, mediated via anti-inflammatory and antioxidant properties. Here, we investigated whether the antenatal administration of lactoferrin (1) improves hippocampal structure, (2) promotes neuronal growth, and (3) mitigates neuroinflammation in the hippocampus of fetal sheep with FGR. Early-onset FGR was induced by performing single umbilical artery ligation surgery on ovine fetuses at ~89 days gestational age (dGA; term ~148 dGA), compared with appropriate for gestational age (AGA) controls. Lactoferrin supplementation to the ewe commenced at 95 dGA (oral, 36 g/day) and continued until 127 dGA (fetal group) or birth (newborn group). Experimental fetal groups included control appropriate for gestational age (AGA; n = 8), FGR (n = 5), control + lactoferrin (AGA + Lacto; n = 6), and FGR + lactoferrin (FGR + Lacto; n = 6). In the fetal group, results showed that neither FGR nor lactoferrin altered hippocampal structure at 127 dGA. Lactoferrin exposure significantly increased neuronal abundance but also altered neuronal morphology. Lactoferrin increased the neurotrophic factor, brain-derived neurotrophic factor (BDNF) in the hippocampus. Lactoferrin exerted region-specific anti-inflammatory effects, with reduced total microglial cell count and resting microglia count in the

Indexed as

Fetal Growth RetardationFetusHippocampusLactoferrinAnimalsBrain-Derived Neurotrophic FactorFemalePregnancySheepBrain-Derived Neurotrophic FactorLactoferrinbrain injurybrain pathologycardiovascularfetal growth restrictionlactoferrinneuroprotectionpreterm

Identifiers

PMID41439974
PMCPMC12731233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.